



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Methicillin-Resistant Staphylococcus aureus (MRSA) - 5EU Drug Forecast and Market Analysis to 2024

Methicillin-Resistant Staphylococcus aureus (MRSA) - 5EU Drug Forecast and Market Analysis to 2024

Publication ID:

GDA1215624

Publication Date:

December 16, 2015

Pages:

328

Publisher:

GlobalData

Region:

Europe [1]

\$6,995.00

Publication License Type *

Single User License (PDF), \$6,995.00

Site License (PDF), \$13,990.00

Global License (PDF), \$20,985.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

Methicillin-Resistant Staphylococcus aureus (MRSA) - 5EU Drug Forecast and Market Analysis to 2024

Summary

With the discovery of penicillin, the first naturally-occurring antibiotic, in 1928, and its mass production in the early 1940s, infections with Staphylococcus aureus were mostly treatable, without any major complications. However, clinicians soon observed the emergence of penicillin-resistant strains of S. aureus, which was largely driven by bacterial expression of beta-lactamases. Methicillin, a novel penicillin analogue that was resistant to beta-lactamases, was introduced in 1959, and was initially effective against penicillin-resistant S. aureus strains. However, this success was short-lived, as the first methicillin-resistant S. aureus (MRSA) strain had been identified in the lab by 1961, and cases of MRSA were first observed in the clinic in 1968. Initially, MRSA strains only occurred in small and local outbreaks across the US and Europe, but they can now be found around the world.

For the purposes of this report, GlobalData defines the 5EU MRSA market as encompassing the sales of antimicrobial agents prescribed for the treatment of hospitalized MRSA skin infections, pneumonia, and bacteremia in France, Germany, Italy, Spain, and the UK. Importantly, revenues generated by these products outside of the aforementioned countries, patient populations, and clinical scenarios are beyond the scope of this analysis.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of MRSA including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU MRSA market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for MRSA.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2014-2024 in 5EU.

Table Of Contents:

- 1 Table of Contents
 - 1.1 List of Tables
 - 1.2 List of Figures
- 2 Introduction
 - 2.1 Catalyst
 - 2.2 Related Reports
 - 2.3 Upcoming Related Reports
- 3 Disease Overview
 - 3.1 Etiology
 - 3.1.1 MRSA Strains
 - 3.1.2 VISA Strains
 - 3.1.3 VRSA Strains
 - 3.2 Pathophysiology
 - 3.2.1 Infection Sites
 - 3.2.2 Expression of Virulence Factors
 - 3.2.3 Mechanisms of Antibiotic Resistance
 - 3.2.4 Biofilm Formation
 - 3.3 Symptoms
 - 3.4 Prognosis
 - 3.4.1 Skin and Soft Tissue Infections
 - 3.4.2 Pneumonia
 - 3.4.3 Bacteremia
 - 3.4.4 Chronic MRSA Infection
- 4 Disease Management
 - 4.1 Diagnosis and Treatment Overview
 - 4.1.1 Diagnosis
 - 4.1.2 Treatment Guidelines
 - 4.1.3 Clinical Practice
 - 4.2 5EU
 - 4.2.1 Forecast
 - 4.2.2 Key Events
 - 4.2.3 Drivers and Barriers
- 5 Competitive Assessment
 - 5.1 Overview
 - 5.2 Product Profiles - Glycopeptides and Lipoglycopeptides
 - 5.2.1 Vancomycin
 - 5.2.2 Dalvance (dalbavancin)

5.2.3 Orbactiv (oritavancin)

5.2.4 Vibativ (telavancin)

5.2.5 Targocid (teicoplanin)

5.3 Product Profiles - Lipopeptides

5.3.1 Cubicin (daptomycin)

5.4 Product Profiles - Oxazolidinones

5.4.1 Zyvox (linezolid)

5.4.2 Sivextro (tedizolid phosphate)

5.5 Product Profiles - Cephalosporins

5.5.1 Teflaro (ceftaroline fosamil)

5.5.2 Zevtera (ceftobiprole medocaril)

5.6 Product Profiles - Glycylcyclines

5.6.1 Tygacil (tigecycline)

5.7 Other Antimicrobial Agents

6 Unmet Need and Opportunity

6.1 Overview

6.2 Drugs with Demonstrated Efficacy in Difficult-to-Treat Patient Populations

6.2.1 Unmet Need

6.2.2 Gap Analysis

6.2.3 Opportunity

6.3 Expand Breadth of Clinical Data Outside of Skin Infections

6.3.1 Unmet Need

6.3.2 Gap Analysis

6.3.3 Opportunity

6.4 Physician Education

6.4.1 Unmet Need

6.4.2 Gap Analysis

6.4.3 Opportunity

6.5 Antibiotics with More Convenient Formulations and Dosing Schedules

6.5.1 Unmet Need

6.5.2 Gap Analysis

6.5.3 Opportunity

6.6 Innovative Approaches to Clinical Trial Design

6.6.1 Unmet Need

6.6.2 Gap Analysis

6.6.3 Opportunity

6.7 Drugs with Novel Mechanisms of Action

6.7.1 Unmet Need

6.7.2 Gap Analysis

6.7.3 Opportunity

- 6.8 More Affordable Therapies
 - 6.8.1 Unmet Need
 - 6.8.2 Gap Analysis
 - 6.8.3 Opportunity
- 7 Pipeline Assessment
 - 7.1 Overview
 - 7.2 Promising Drugs in Late-Stage Clinical Development
 - 7.2.1 Delafloxacin (RX-3341)
 - 7.2.2 Solithromycin (CEM-101)
 - 7.2.3 Omadacycline (PTK-0796)
 - 7.2.4 KRP-AM1977X
 - 7.2.5 Taksta (fusidic acid, oral tablets)
 - 7.2.6 Lefamulin (BC-3781)
 - 7.2.7 Debio1450 (Debio1452 prodrug)
 - 7.2.8 Brilacidin
 - 7.3 Other Promising Products in Clinical Development
- 8 Market Outlook
 - 8.1 5EU
 - 8.1.1 Forecast
 - 8.1.2 Key Events
 - 8.1.3 Drivers and Barriers
- 9 Appendix
 - 9.1 Bibliography
 - 9.2 Abbreviations
 - 9.3 Methodology
 - 9.4 Forecasting Methodology
 - 9.4.1 Hospitalized MRSA Patients
 - 9.4.2 Percentage of Drug-Treated MRSA Patients
 - 9.4.3 Drugs Included in Each Therapeutic Class
 - 9.4.4 Launch, Label Expansion, and Patent Expiry Dates
 - 9.4.5 General Pricing Assumptions
 - 9.4.6 Individual Drug Assumptions
 - 9.4.7 Generic Erosion
 - 9.4.8 Pricing of Pipeline Agents
 - 9.5 Primary Research - KOLs Interviewed for This Report
 - 9.6 Primary Research - Prescriber Survey
 - 9.7 About the Authors
 - 9.7.1 Author and Therapy Area Director
 - 9.7.2 Author
 - 9.7.3 Epidemiologist

9.7.4 Global Director of Therapy Analysis and Epidemiology

9.7.5 Global Head of Healthcare

9.8 About GlobalData

9.9 Disclaimer

1.1 List of Tables

Table 1: Symptoms of MRSA-Associated Infections

Table 2: National and International Treatment Guidelines for MRSA Infections

Table 3: Sales Forecasts (\$m) for MRSA in the 5EU, 2014-2024

Table 4: Key Events Impacting Sales for MRSA in the 5EU, 2014-2024

Table 5: MRSA Therapeutics Market - Drivers and Barriers in the 5EU, 2014-2024

Table 6: National Healthcare Authorities and Government Drug Pricing Authorities in the 5EU Nations

Table 7: Leading Branded Treatments for MRSA, 2015

Table 8: Product Profile - Vancomycin

Table 9: Vancomycin SWOT Analysis, 2015

Table 10: Global Sales Forecasts (\$m) for Vancomycin, 2014-2024

Table 11: Product Profile - Dalvance

Table 12: Efficacy of Dalvance - Primary and Secondary Endpoints, DISCOVER 1 and DISCOVER 2

Table 13: Safety of Dalvance - Frequency of AEs, DISCOVER 1 and DISCOVER 2

Table 14: Dalvance SWOT Analysis, 2015

Table 15: Global Sales Forecasts (\$m) for Dalvance, 2014-2024

Table 16: Product Profile - Orbactiv

Table 17: Efficacy of Orbactiv - Primary and Secondary Endpoints, SOLO I and SOLO II

Table 18: Safety of Orbactiv - Frequency of AEs, SOLO I and SOLO II

Table 19: Orbactiv SWOT Analysis, 2015

Table 20: Global Sales Forecasts (\$m) for Orbactiv, 2014-2024

Table 21: Product Profile - Vibativ

Table 22: Efficacy of Vibativ - Pooled Primary and Secondary Endpoints, ATLAS 1 and ATLAS 2

Table 23: Safety of Vibativ - Frequency of AEs, ATLAS and ATTAIN Phase III Programs

Table 24: Vibativ SWOT Analysis, 2015

Table 25: Global Sales Forecasts (\$m) for Vibativ, 2014-2024

Table 26: Product Profile - Targocid

Table 27: Targocid SWOT Analysis, 2015

Table 28: Global Sales Forecasts (\$m) for Targocid, 2014-2024

Table 29: Product Profile - Cubicin

Table 30: Efficacy of Cubicin - Pooled Clinical Success Rates by Causative Pathogen, cSSSI Trials

Table 31: Safety of Cubicin - Frequency of AEs and SAEs

Table 32: Cubicin SWOT Analysis, 2015

Table 33: Global Sales Forecasts (\$m) for Cubicin, 2014-2024

Table 34: Product Profile - Zyvox

Table 35: Efficacy of Zyvox - Primary and Secondary Endpoints, cSSSI Study in Adults

Table 36: Safety of Zyvox - Frequency of Treatment-Emergent AEs

Table 37: Zyvox SWOT Analysis, 2015

Table 38: Global Sales Forecasts (\$m) for Zyvox, 2014-2024

Table 39: Product Profile - Sivextro

Table 40: Efficacy of Sivextro - Primary and Secondary Endpoints, ESTABLISH Phase III Program

Table 41: Safety of Sivextro - Frequency of Treatment-Emergent AEs, ESTABLISH-1 and ESTABLISH-2

Table 42: Sivextro SWOT Analysis, 2015

Table 43: Global Sales Forecasts (\$m) for Sivextro, 2014-2024

Table 44: Product Profile - Teflaro

Table 45: Efficacy of Teflaro - Pooled Primary and Secondary Endpoints, FOCUS 1 and FOCUS 2

Table 46: Safety of Teflaro - Frequency of AEs, FOCUS and CANVAS Phase III Programs

Table 47: Teflaro SWOT Analysis, 2015

Table 48: Global Sales Forecasts (\$m) for Teflaro, 2014-2024

Table 49: Product Profile - Zevtera

Table 50: Efficacy of Zevtera - Primary and Endpoints, HABP and CABP Phase III Studies

Table 51: Safety of Zevtera - Frequency of AEs, HABP and CABP Phase III Studies

Table 52: Zevtera SWOT Analysis, 2015

Table 53: Global Sales Forecasts (\$m) for Zevtera, 2014-2024

Table 54: Product Profile - Tygacil

Table 55: Tygacil SWOT Analysis, 2015

Table 56: Global Sales Forecasts (\$m) for Tygacil, 2014-2024

Table 57: Summary of Other Antimicrobial Agents Used for S. aureus and MRSA, 2015

Table 58: Unmet Need and Opportunity in MRSA, 2015

Table 59: Key Late-Stage Pipeline Agents for MRSA, 2015

Table 60: Product Profile - Delafloxacin

Table 61: Delafloxacin SWOT Analysis, 2015

Table 62: Global Sales Forecasts (\$m) for Delafloxacin, 2014-2024

Table 63: Product Profile - Solithromycin

Table 64: Solithromycin SWOT Analysis, 2015

Table 65: Global Sales Forecasts (\$m) for Solithromycin, 2014-2024

Table 66: Product Profile - Omadacycline

Table 67: Omadacycline SWOT Analysis, 2015

Table 68: Global Sales Forecasts (\$m) for Omadacycline, 2014-2024

Table 69: Product Profile - KRP-AM1977X

Table 70: KRP-AM1977X SWOT Analysis, 2015

Table 71: Global Sales Forecasts (\$m) for KRP-AM1977X, 2014-2024

Table 72: Product Profile - Taksta

Table 73: Taksta SWOT Analysis, 2015

Table 74: Global Sales Forecasts (\$m) for Taksta, 2014-2024

Table 75: Product Profile - Lefamulin

Table 76: Lefamulin SWOT Analysis, 2015

Table 77: Global Sales Forecasts (\$m) for Lefamulin, 2014-2024

Table 78: Product Profile - Debio1450

Table 79: Debio1450 SWOT Analysis, 2015

Table 80: Global Sales Forecasts (\$m) for Debio1450, 2014-2024

Table 81: Product Profile - Brilacidin

Table 82: Brilacidin SWOT Analysis, 2015

Table 83: Global Sales Forecasts (\$m) for Brilacidin, 2014-2024

Table 84: Other Promising Pipeline Products for MRSA, 2015

Table 85: Sales Forecasts (\$m) for MRSA in the 5EU, 2014-2024

Table 86: Key Events Impacting Sales for MRSA in the 5EU, 2014-2024

Table 87: MRSA Therapeutics Market - Drivers and Barriers in the 5EU, 2014-2024

Table 88: National Healthcare Authorities and Government Drug Pricing Authorities in the 5EU Nations

Table 89: Key Historical and Projected Launch Dates for MRSA Across the 7MM

Table 90: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM

Table 91: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM

Table 92: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures

Figure 1: The MRSA SCCmec Gene Cluster

Figure 2: Sites of *S. aureus* Infection

Figure 3: Cartoon Depicting the Key Mechanisms of Antibiotic Resistance Observed in *S. aureus*

Figure 4: Sales for MRSA Therapeutics by Drug Class in the 5EU, 2014 and 2024

Figure 5: Sales for MRSA Therapeutics by Country in the 5EU, 2014-2024

Figure 6: MRSA Therapeutics - Phase III/Phase II Pipeline, 2015

Figure 7: Competitive Assessment of the Recently Approved and Late-Stage Pipeline Agents in MRSA, 2014-2024

Figure 8: Sales for MRSA Therapeutics by Drug Class in the 5EU, 2014 and 2024

Figure 9: Sales for MRSA Therapeutics by Country in the 5EU, 2014-2024

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.

- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

-->

NAVIGATE

About Us

Reports by Region

FAQ

Privacy Policy

TERMS & CONDITIONS

CONTACT

RECENT POSTS

What is drug pipeline research?

March 20

How to use market research to bring your idea to life?

March 11

How to gain business insights using syndicated market research?

March 10

Source URL: <https://www.drugpipeline.net/globaldata/methicillin-resistant-staphylococcus-aureus-mrsa-5eu-drug-f-recast-and-market-analysis>

Links

[1] <https://www.drugpipeline.net/region/europe>